Phase 1Completed

TMC435-TiDP16-C115 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and Erythromycin and Between TMC435 and Darunavir/Ritonavir (DRV/r)

A Phase I, 2-panel, Open-label, Randomized, Crossover Trial in Healthy Subjects to Investigate the Pharmacokinetic Interaction Between TMC435 and CYP3A Inhibitors, Erythromycin and Darunavir/Ritonavir (DRV/r)

Sponsor
Tibotec Pharmaceuticals, Ireland (Industry)
Enrollment
49 enrolled
Conditions
Hepatitis C Virus
Interventions
erythromycin; Ritonavir; TMC435; Darunavir; TMC435; erythromycin
Ages
adults
Registry
NCT01323257

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to investigate the effect of steady-state concentrations of erythromycin or DRV/r on the steady-state pharmacokinetics of TMC435, the effect of a steady-state concentration of TMC435 (150 mg) on the steady-state pharmacokinetics of erythromycin and the effect of a steady-state concentration of TMC435 (50 mg) on the steady-state pharmacokinetics of DRV/r. We will also study the short-term safety and tolerability of TMC435 given alone and given togehter with erythromycin (Panel 1) or DRV/r (Panel 2). Steady state is a term that means that the drug has been given long enough so that the plasma concentrations will remain the same with each subsequent dose. TMC435 is being investigated for the treatment of chronic hepatitis C virus (HCV) infection. Pharmacokinetics (PK) means how the drug is absorbed into the bloodstream, distributed in the body, and eliminated from the body.

Primary outcomes

  • Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with erythromycin (Panel 1).
  • Change in the steady-state plasma pharmacokinetics of TMC435 following co-administration with DRV/r (Panel 2).

History

  1. Last registry update

  2. Study completion

  3. Registered

  4. Started